Highest-materiality recent filing
ArriVent reports FY2025 net loss of $166.3M; cash of $312.8M funds into 3Q 2027
Cash and investments of $312.8M as of Dec 31, 2025; expected to fund operations into 3Q 2027.
ArriVent reports Q3 net loss $130.8M; cash $305.4M funds into mid-2027
Net loss $130.8M for nine months ended Sep 30, 2025, up from $59.9M in 2024, driven by R&D spend including $40M upfront for ARR-217.
ArriVent reports 16.0-month mPFS with firmonertinib in EGFR PACC NSCLC Phase 1b final analysis
Median PFS 16.0 months by BICR with firmonertinib 240 mg once daily in first-line EGFR PACC NSCLC.
ArriVent Q2 2025 net loss $95.8M; firmonertinib PACC data positive; ADC ARR-217 dosed
Cash and investments $254.5M at June 30, plus $81.1M raised in July 2025 public offering; runway extended to mid-2027.
ArriVent BioPharma prices $75M public offering of common stock and pre-funded warrants
Raised ~$75M gross; priced 2,482,692 shares at $19.50 and 1,363,469 pre-funded warrants at $19.4999.
Positive Phase 1b firmonertinib data; 16.0 mo mPFS at 240 mg; global Phase 3 ALPACCA planned H2 2025
16.0 months median PFS by BICR at 240 mg dose in first-line EGFR PACC mutant NSCLC; 68.2% confirmed ORR at 240 mg.
ArriVent Q1 cash $205.5M, net loss $64.4M; Phase 3 enrollment completed for firmonertinib
Cash $205.5M as of March 31, 2025; net loss $64.4M (vs $17.4M YoY) due to $40M upfront payment to Lepu for ARR-217.
ArriVent reports FY2024 net loss $80.5M; cash $266.5M; Phase 3 trial enrollment achieved
Cash and investments of $266.5M as of Dec 31, 2024; expected to fund operations into 2026.
ArriVent licenses ADC MRG007 from Lepu Biopharma; upfront $47M, total potential $1.16B
Exclusive global rights outside Greater China for MRG007, a preclinical ADC targeting GI cancers.
Cash and cash equivalents $282.9M as of Sept 30, 2024; expected to fund operations into 2026.
ArriVent: firmonertinib shows 81.8% ORR in EGFR PACC mutant NSCLC Phase 1b data
81.8% ORR and 63.6% confirmed ORR by BICR at 240mg dose in first-line EGFR PACC mutant NSCLC.
ArriVent Q2 net loss $39.3M; cash $298.7M funds into 2026; firmonertinib data at WCLC
Net loss for six months ended June 30, 2024 was $39.3M, compared to $33.7M in prior year period.
ArriVent BioPharma enters ADC collaboration with Alphamab; milestones up to $615.5M
Collaboration to discover, develop, and commercialize novel antibody drug conjugates (ADCs) for cancers.
ArriVent Q1 net loss $17.4M; cash $317.4M; fully enrolled PACC cohort, initiated combo study
Cash and equivalents $317.4M as of March 31, 2024, expected to fund operations into 2026.
ArriVent BioPharma completes IPO of 9.7M shares at $18, raising ~$175M
IPO of 9,722,222 shares of common stock at $18.00 per share closed January 30, 2024.
the Board approved, effective April 28, 2025, an increase in the size of the Board from seven (7) directors to eight (8) directors and appointed Merdad Parsey, M.D., Ph.D. to fill the newly created vacancy on the Board
On April 23, 2025, Carl L. Gordon, Ph.D., CFA notified the board of directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) of his decision not to stand for re-election to the Board at the end of his current term at the Company’s 2025 annual meeting of stockholders currently expected to be held on June 18, 2025
On April 20, 2024, the Board of Directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) appointed Kristine Peterson to the Board, effective immediately (the “Effective Date”).
On May 16, 2024, the Board of Directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) appointed John Hohneker, M.D., to the Board, effective as of May 16, 2024 (the “Effective Date”).
On April 20, 2024, the Board of Directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) appointed Kristine Peterson to the Board, effective immediately
Max materiality 0.80 · Median 0.60 · Most common event other_material